• Policy
• It is impossible to exclude PVA from domestic new drugs
• by Lee, Jeong-Hwan Nov 2, 2021 05:54am

• Policy
• 342 items unable for supply voluntarily withdraw listing
• by Lee, Hye-Kyung Nov 2, 2021 05:53am

• Policy
• Is the first generic release of the ADHD tx Concerta?
• by Lee, Tak-Sun Nov 2, 2021 05:53am

• Policy
• Generics for Jardiance have obtained generic for exclusivity
• by Lee, Tak-Sun Nov 2, 2021 05:53am

• Policy
• Redundancies in CDRD and PBAC roles in continuous dispute
• by Lee, Hye-Kyung Nov 1, 2021 05:56am

• Policy
• HIRA clarifies ‘Opdivo·Keytruda·Tecentriq’ eligibility
• by Lee, Hye-Kyung Nov 1, 2021 05:56am

• Policy
• Concerns about the introduction of the Reference Price
• by Kim, Jung-Ju Nov 1, 2021 05:55am

• Policy
• 'Symbenda' withdraws from Korean market 3 years after reimb.
• by Lee, Tak-Sun Oct 29, 2021 05:54am

• Policy
• KDCA “will monitor development of oral COVID-19 treatments"
• by Lee, Hye-Kyung Oct 29, 2021 05:53am

• Policy
• The government needs to create a sovereign wealth fund
• by Lee, Jeong-Hwan Oct 29, 2021 05:53am